What is LPIXEL?
Established in March 2014 as a spin-off from the University of Tokyo, LPIXEL Inc. specializes in leveraging artificial intelligence to develop sophisticated software solutions for the medical, pharmaceutical, and agricultural industries. The company's core offerings include EIRL, an AI-driven diagnostic support tool for medical imaging, and IMACEL, an AI platform designed to enhance efficiency in drug discovery processes. Through collaborations with prominent institutions like the University of Tokyo and the National Cancer Center Japan, LPIXEL is at the forefront of advancing AI-powered medical diagnostics and research.
How much funding has LPIXEL raised?
LPIXEL has raised a total of $30M across 1 funding round:
Series A
$30M
Series A (2018): $30M, investors not publicly disclosed
What's next for LPIXEL?
The recent major strategic investment signals a pivotal growth phase for LPIXEL, likely enabling the company to accelerate the development and commercialization of its AI-powered image analysis technologies. This capital infusion is expected to bolster its market presence in medical diagnostics and drug discovery, potentially leading to expanded research initiatives and strategic partnerships. The company's focus on integrating AI into critical life science applications positions it for significant future expansion and innovation.
See full LPIXEL company page
